Review
Open access
Sep 2026
Evolution of darolutamide evidence base: review of new data from international congresses and their role in personalization of systemic therapy selection
The ARASAFE, ARASEC, and ARACOG studies, the results of which were presented at major international congresses in 2026, are designed to address gaps in the transition toward a personalized model of systemic therapy selection for patients with advanced prostate cancer.
V. Matveev, A. Klimov, N. D. Novichkov
· Cancer Urology · 0 citations